An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer

被引:78
|
作者
Rimm, David L. [1 ]
Leung, Samuel C. Y. [2 ]
McShane, Lisa M. [3 ]
Bai, Yalai [1 ]
Bane, Anita L. [4 ]
Bartlett, John M. S. [5 ,6 ]
Bayani, Jane [5 ]
Chang, Martin C. [7 ]
Dean, Michelle [8 ]
Denkert, Carsten [9 ,10 ]
Enwere, Emeka K. [8 ]
Galderisi, Chad [11 ]
Gholap, Abhi [12 ]
Hugh, Judith C. [13 ]
Jadhav, Anagha [12 ]
Kornaga, Elizabeth N. [8 ]
Laurinavicius, Arvydas [14 ]
Levenson, Richard [15 ]
Lima, Joema [5 ]
Miller, Keith [16 ]
Pantanowitz, Liron [17 ]
Piper, Tammy [6 ]
Ruan, Jason [15 ]
Srinivasan, Malini [17 ]
Virk, Shakeel [18 ]
Wu, Ying [4 ]
Yang, Hua [13 ]
Hayes, Daniel F. [19 ]
Nielsen, Torsten O. [2 ]
Dowsett, Mitch [20 ]
机构
[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[2] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada
[3] NCI, Biometr Res Program, Div Canc Treatment & Diag, Bethesda, MD 20892 USA
[4] McMaster Univ, Juravinski Hosp & Canc Ctr, Dept Pathol & Mol Med, Hamilton, ON, Canada
[5] Ontario Inst Canc Res, Transformat Pathol, Toronto, ON, Canada
[6] Edinburgh Canc Res Ctr, Biomarkers & Compan Diagnost Grp, Edinburgh, Midlothian, Scotland
[7] Univ Toronto, Sinai Hlth Syst, Toronto, ON, Canada
[8] Alberta Hlth Serv, Tom Baker Canc Ctr, Translat Labs, Calgary, AB, Canada
[9] Charite Campus Mitte, Inst Pathol, Berlin, Germany
[10] Charite Campus Mitte, German Canc Consortium DKTK, Berlin, Germany
[11] MolecularMD, Portland, OR USA
[12] NeoPro SEZ, Optra Technol, Blue Ridge, Hinjewadi, India
[13] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada
[14] Vilnius Univ, Vilnius Univ Hosp Santara Clin, Natl Ctr Pathol, Vilnius, Lithuania
[15] Univ Calif Davis, Med Ctr, Dept Med Pathol & Lab Med, Sacramento, CA 95817 USA
[16] Poundbury Canc Inst, Canc Diagnost Qual Assurance Serv CIC, Poundbury, DT, England
[17] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA
[18] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada
[19] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Breast Oncol Program, Ann Arbor, MI 48109 USA
[20] Inst Canc Res, London, England
关键词
D O I
10.1038/s41379-018-0109-4
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The nuclear proliferation biomarker Ki67 has potential prognostic, predictive, and monitoring roles in breast cancer. Unacceptable between-laboratory variability has limited its clinical value. The International Ki67 in Breast Cancer Working Group investigated whether Ki67 immunohistochemistry can be analytically validated and standardized across laboratories using automated machine-based scoring. Sets of pre-stained core-cut biopsy sections of 30 breast tumors were circulated to 14 laboratories for scanning and automated assessment of the average and maximum percentage of tumor cells positive for Ki67. Seven unique scanners and 10 software platforms were involved in this study. Pre-specified analyses included evaluation of reproducibility between all laboratories (primary) as well as among those using scanners from a single vendor (secondary). The primary reproducibility metric was intraclass correlation coefficient between laboratories, with success considered to be intraclass correlation coefficient > 0.80. Intraclass correlation coefficient for automated average scores across 16 operators was 0.83 (95% credible interval: 0.73-0.91) and intraclass correlation coefficient for maximum scores across 10 operators was 0.63 (95% credible interval: 0.44-0.80). For the laboratories using scanners from a single vendor (8 score sets), intraclass correlation coefficient for average automated scores was 0.89 (95% credible interval: 0.81-0.96), which was similar to the intraclass correlation coefficient of 0.87 (95% credible interval: 0.81-0.93) achieved using these same slides in a prior visual-reading reproducibility study. Automated machine assessment of average Ki67 has the potential to achieve between-laboratory reproducibility similar to that for a rigorously standardized pathologist-based visual assessment of Ki67. The observed intraclass correlation coefficient was worse for maximum compared to average scoring methods, suggesting that maximum score methods may be suboptimal for consistent measurement of proliferation. Automated average scoring methods show promise for assessment of Ki67 scoring, but requires further standardization and subsequent clinical validation.
引用
收藏
页码:59 / 69
页数:11
相关论文
共 50 条
  • [41] Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer
    Aleskandarany, M. A.
    Green, A. R.
    Ashankyty, I.
    Elmouna, A.
    Diez-Rodriguez, M.
    Nolan, C. C.
    Ellis, I. O.
    Rakha, E. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (02) : 287 - 295
  • [42] Comparison of manual and digital histopathology scoring for Ki67 in breast cancer core biopsies
    Alataki, Anastasia
    Zabaglo, Lila
    Tovey, Holly
    Dodson, Andrew
    Dowsett, Mitch
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 545 - 546
  • [43] Expression, assessment and significance of Ki67 expression in breast cancer: an update
    Lashen, Ayat Gamal
    Toss, Michael S.
    Ghannam, Suzan Fathy
    Makhlouf, Shorouk
    Green, Andrew
    Mongan, Nigel P.
    Rakha, Emad
    JOURNAL OF CLINICAL PATHOLOGY, 2023, 76 (06) : 357 - 364
  • [44] A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study
    Bahaddin, Mowafak Masoud
    ANNALS OF MEDICINE AND SURGERY, 2020, 60 : 232 - 235
  • [45] Ki67 in young patients with breast cancer
    Vasseur, F.
    Baranzelli, M. -C.
    Fournier, C.
    Bonneterre, J.
    GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2013, 41 (01): : 16 - 19
  • [46] To Count or Not To Count? Scoring Ki67 in Breast Cancers According to International Working Group Recommendations
    Adamson, K. H.
    Konnick, E. Q.
    Dintzis, S. M.
    Rendi, M. H.
    Linden, H. M.
    Allison, K. H.
    MODERN PATHOLOGY, 2013, 26 : 26A - 26A
  • [47] To Count or Not To Count? Scoring Ki67 in Breast Cancers According to International Working Group Recommendations
    Adamson, K. h
    Konnick, E. Q.
    Dintzis, S. M.
    Rendi, M. H.
    Linden, H. M.
    Allison, K. H.
    LABORATORY INVESTIGATION, 2013, 93 : 26A - 26A
  • [48] Analytical validation of a standardized scoring protocol for Ki67: Phase-3 of an international multicenter collaboration
    Dowsett, M.
    Leung, S. C. Y.
    Zabaglo, L.
    Arun, I.
    Badve, S. S.
    Bane, A. L.
    Bartlett, J. M. S.
    Borgquist, S.
    Chang, M. C.
    Dodson, A.
    Enos, R. E.
    Fineberg, S.
    Focke, C. M.
    Gao, D.
    Gown, A. M.
    Grabau, D.
    Gutierrez, C.
    Hugh, J. C.
    Kos, Z.
    Laenkholm, A-V
    Lin, M-G
    Mastropasqua, M. G.
    Moriya, T.
    Nofech-Mozes, S.
    Osborne, C. K.
    Penault-Llorca, F. M.
    Piper, T.
    Sakatani, T.
    Salgado, R.
    Starczynski, J.
    Viale, G.
    Hayes, D. F.
    McShane, L. M.
    Nielsen, T. O.
    CANCER RESEARCH, 2016, 76
  • [49] Optimizing the use of Ki67 in breast cancer
    Sundquist, M.
    Holmberg, E.
    Kovacs, A.
    Mellblom, L.
    Bagge, R. Olofsson
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S128 - S128
  • [50] KI67 IN PRIMARY BREAST-CANCER
    ROBERTSON, FR
    WALKER, K
    NICHOLSON, RI
    LOCKER, AP
    ELLIS, IO
    BLAMEY, RW
    BRITISH JOURNAL OF CANCER, 1989, 60 (03) : 487 - 487